Citicoline Sodium | CAS#33818-15-4 | neuroprotective agent

Citicoline Sodium
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 563366

CAS#: 33818-15-4

Description: Citicoline Sodium is a neuroprotective agent. It acts by enhancing cellular communication, stimulating the synthesis of SAMe, and increasing glucose metabolism.

Chemical Structure

Citicoline Sodium

CAS# 33818-15-4

Instruction

Theoretical Analysis

MedKoo Cat#: 563366
Name: Citicoline Sodium
CAS#: 33818-15-4
Chemical Formula: C14H25N4NaO11P2
Exact Mass: 0.00
Molecular Weight: 510.300
Elemental Analysis: C, 32.95; H, 4.94; N, 10.98; Na, 4.51; O, 34.49; P, 12.14

Price and Availability

Size	Price	Availability
1g	USD 250	2 Weeks
5g	USD 550	2 Weeks
10g	USD 850	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Citicoline Sodium; Citicoline Na; Citicolinesodium; Cytidine 5'-diphosphocholine sodium; Cdp-choline sodium;

IUPAC/Chemical Name: Sodium [[(2S,3R,4S,5S)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] 2-(trimethylazaniumyl)ethyl phosphate

InChi Key: YWAFNFGRBBBSPD-KDVMHAGBSA-M

InChi Code: InChI=1S/C14H26N4O11P2.Na/c1-18(2,3)6-7-26-30(22,23)29-31(24,25)27-8-9-11(19)12(20)13(28-9)17-5-4-10(15)16-14(17)21;/h4-5,9,11-13,19-20H,6-8H2,1-3H3,(H3-,15,16,21,22,23,24,25);/q;+1/p-1/t9-,11-,12-,13-;/m0./s1

SMILES Code: O=P(OP([O-])(OC[C@@H]1O[C@H](N2C=CC(N)=NC2=O)[C@@H](O)[C@H]1O)=O)([O-])OCC[N+](C)(C)C.[Na+]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 510.30 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Tyurenkov IN, Kurkin DV, Bakulin DA, Volotova EV, Chafeev MA. [Cerebroprotective activity of metformin, gosogliptin, citicoline and a novel GPR119 agonist in cerebral ischemia under experimental diabetes mellitus]. Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(12. Vyp. 2):53-59. doi: 10.17116/jnevro201711712253-59. Russian. PubMed PMID: 29411746.

2: Jiang JJ, Xie YM, Zhang Y, Zhang YK, Wang ZM, Han B. [Clinical medication characteristics of Shuxuening injection in treatment of cerebral infarction research based on registration]. Zhongguo Zhong Yao Za Zhi. 2016 Dec;41(24):4516-4520. doi: 10.4268/cjcmm20162407. Chinese. PubMed PMID: 28936832.

3: Liu Y, Wang J, Xu C, Chen Y, Yang J, Liu D, Niu H, Jiang Y, Yang S, Ying H. Efficient multi-enzyme-catalyzed CDP-choline production driven by an ATP donor module. Appl Microbiol Biotechnol. 2017 Feb;101(4):1409-1417. doi: 10.1007/s00253-016-7874-0. Epub 2016 Oct 13. PubMed PMID: 27738720.

4: Wang NQ, Wang LY, Zhao HP, Liu P, Wang RL, Song JX, Gao L, Ji XM, Luo YM. Luoyutong Treatment Promotes Functional Recovery and Neuronal Plasticity after Cerebral Ischemia-Reperfusion Injury in Rats. Evid Based Complement Alternat Med. 2015;2015:369021. doi: 10.1155/2015/369021. Epub 2015 Dec 1. PubMed PMID: 26697095; PubMed Central PMCID: PMC4678236.

5: Tang Y, Shang Q. [Neonatal hypoxic ischemic encephalopathy treated with acupuncture combined with acupoint injection: a randomized controlled trial]. Zhongguo Zhen Jiu. 2015 Jul;35(7):641-5. Chinese. PubMed PMID: 26521569.

6: Tang Y, Shang Q, Zhou LH. [Vegetative state treated with acupoint injection combined with plum-blossom needle in children: a randomized controlled trial]. Zhongguo Zhen Jiu. 2014 May;34(5):421-5. Chinese. PubMed PMID: 25022107.

7: Maradiya HK, Pansara VH. Development and Validation of Reverse-phase High-performance Liquid Chromatography Method for Estimation of Citicoline Sodium in Bulk and Dosage Form. Indian J Pharm Sci. 2013 Mar;75(2):238-41. PubMed PMID: 24019577; PubMed Central PMCID: PMC3757867.

8: Zhang LN, Sun YJ, Pan S, Li JX, Qu YE, Li Y, Wang YL, Gao ZB. Na⁺-K⁺-ATPase, a potent neuroprotective modulator against Alzheimer disease. Fundam Clin Pharmacol. 2013 Feb;27(1):96-103. doi: 10.1111/fcp.12000. Epub 2012 Oct 3. Review. PubMed PMID: 23033963.

9: Ali Mousavi S, Khorvash F, Hoseini T. The efficacy of citroline in the treatment of ischemic stroke and primary hypertensive intracereral hemorrhage; a review article. ARYA Atheroscler. 2010 Fall;6(3):122-5. PubMed PMID: 22577428; PubMed Central PMCID: PMC3347821.

10: Kamei J, Ohsawa M, Miyata S, Endo K, Hayakawa H. Effects of cytidine 5'-diphosphocholine (CDP-choline) on the thermal nociceptive threshold in streptozotocin-induced diabetic mice. Eur J Pharmacol. 2008 Nov 19;598(1-3):32-6. doi: 10.1016/j.ejphar.2008.09.012. Epub 2008 Sep 22. PubMed PMID: 18834878.

11: Hartvigsen K, Ravandi A, Harkewicz R, Kamido H, Bukhave K, Hølmera G, Kuksis A. 1 -O-alkyl-2-(omega-oxo)acyl-sn-glycerols from shark oil and human milk fat are potential precursors of PAF mimics and GHB. Lipids. 2006 Jul;41(7):679-93. PubMed PMID: 17069352.

12: Schuettauf F, Rejdak R, Thaler S, Bolz S, Lehaci C, Mankowska A, Zarnowski T, Junemann A, Zagorski Z, Zrenner E, Grieb P. Citicoline and lithium rescue retinal ganglion cells following partial optic nerve crush in the rat. Exp Eye Res. 2006 Nov;83(5):1128-34. Epub 2006 Jul 28. PubMed PMID: 16876158.

13: Ferro JM, Dávalos A. Other neuroprotective therapies on trial in acute stroke. Cerebrovasc Dis. 2006;21 Suppl 2:127-30. Epub 2006 May 2. PubMed PMID: 16651823.

14: Lizasoain I, Cárdenas A, Hurtado O, Romera C, Mallolas J, Lorenzo P, Castillo J, Moro MA. Targets of cytoprotection in acute ischemic stroke: present and future. Cerebrovasc Dis. 2006;21 Suppl 2:1-8. Epub 2006 May 2. PubMed PMID: 16651809.

15: Nikolov R. Alzheimer's disease therapy - an update. Drug News Perspect. 1998 May;11(4):248-55. PubMed PMID: 15616667.

16: Tasseva G, Richard L, Zachowski A. Regulation of phosphatidylcholine biosynthesis under salt stress involves choline kinases in Arabidopsis thaliana. FEBS Lett. 2004 May 21;566(1-3):115-20. PubMed PMID: 15147879.

17: Conant R, Schauss AG. Therapeutic applications of citicoline for stroke and cognitive dysfunction in the elderly: a review of the literature. Altern Med Rev. 2004 Mar;9(1):17-31. Review. PubMed PMID: 15005642.

18: Plataras C, Angelogianni P, Tsakiris S. Effect of CDP-choline on hippocampal acetylcholinesterase and Na+,K(+)-ATPase in adult and aged rats. Z Naturforsch C. 2003 Mar-Apr;58(3-4):277-81. PubMed PMID: 12710741.

19: Zufferey R, Mamoun CB. Choline transport in Leishmania major promastigotes and its inhibition by choline and phosphocholine analogs. Mol Biochem Parasitol. 2002 Nov-Dec;125(1-2):127-34. PubMed PMID: 12467980.

20: Ohkawa Y, Kiyohara Y, Asoh T, Maeda H, Kurumi M, Sasaki K, Kurosaki Y, Matsumura M, Nakayama T. Application of 4-hydroxyantipyrine and acetaminophen O-sulfate as biodistribution promoter. Biol Pharm Bull. 2001 Dec;24(12):1404-10. PubMed PMID: 11767111.

Your view history

Citicoline Sodium featured